adenine has been researched along with Lymphocytosis in 16 studies
Lymphocytosis: Excess of normal lymphocytes in the blood or in any effusion.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Lymphocytosis is a common and predictable pharmacodynamic effect of ibrutinib treatment, and in the absence of other signs of progression, does not represent disease progression." | 2.90 | Characterizing the kinetics of lymphocytosis in patients with chronic lymphocytic leukemia treated with single-agent ibrutinib. ( Barrientos, JC; Burger, JA; Byrd, JC; Hillmen, P; James, DF; Kipps, TJ; Ninomoto, J; Zhou, C, 2019) |
| "The kinetics and degree of the treatment-induced lymphocytosis was highly variable; interestingly, in patients with a high baseline ALC the relative increase was mild and resolution rapid." | 2.79 | Ibrutinib-induced lymphocytosis in patients with chronic lymphocytic leukemia: correlative analyses from a phase II study. ( Aue, G; Calvo, KR; Farooqui, M; Geisler, CH; Gyamfi, JA; Herman, SE; Jones, J; Lipsky, A; Liu, D; Maric, I; Marti, GE; Martyr, S; Mustafa, RZ; Niemann, CU; Pedersen, LB; Saba, N; Soto, S; Valdez, J; Wiestner, A, 2014) |
| "Thus, prolonged lymphocytosis is common following ibrutinib treatment, likely represents the persistence of a quiescent clone, and does not predict a subgroup of patients likely to relapse early." | 1.40 | Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy. ( Byrd, JC; Clow, F; Flynn, J; Furman, RR; Ghia, E; James, DF; Johnson, AJ; Jones, J; Kipps, TJ; Lozanski, A; Lozanski, G; Lucas, D; Maddocks, K; Mantel, R; O'Brien, S; Rassenti, L; Ruppert, AS; Smith, LL; Smucker, K; Williams, K; Woyach, JA; Zhao, W; Zhong, Y, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 13 (81.25) | 24.3611 |
| 2020's | 3 (18.75) | 2.80 |
| Authors | Studies |
|---|---|
| Koehler, A | 1 |
| Gallais, F | 1 |
| Ysebaert, L | 1 |
| Despas, F | 1 |
| De Barros, S | 1 |
| Obéric, L | 1 |
| Allal, B | 1 |
| Chatelut, E | 1 |
| White-Koning, M | 1 |
| Paydaş, S | 1 |
| Bayram, E | 1 |
| Türker, M | 1 |
| Özer, T | 1 |
| Ali, N | 1 |
| Malik, F | 1 |
| Jafri, SIM | 1 |
| Naglak, M | 1 |
| Sundermeyer, M | 1 |
| Pickens, PV | 1 |
| Tissino, E | 1 |
| Benedetti, D | 1 |
| Herman, SEM | 1 |
| Ten Hacken, E | 1 |
| Ahn, IE | 1 |
| Chaffee, KG | 1 |
| Rossi, FM | 1 |
| Dal Bo, M | 1 |
| Bulian, P | 1 |
| Bomben, R | 1 |
| Bayer, E | 1 |
| Härzschel, A | 1 |
| Gutjahr, JC | 1 |
| Postorino, M | 1 |
| Santinelli, E | 1 |
| Ayed, A | 1 |
| Zaja, F | 1 |
| Chiarenza, A | 1 |
| Pozzato, G | 1 |
| Chigaev, A | 1 |
| Sklar, LA | 1 |
| Burger, JA | 3 |
| Ferrajoli, A | 2 |
| Shanafelt, TD | 1 |
| Wiestner, A | 3 |
| Del Poeta, G | 1 |
| Hartmann, TN | 1 |
| Gattei, V | 1 |
| Zucchetto, A | 1 |
| Gribben, JG | 1 |
| Bosch, F | 1 |
| Cymbalista, F | 1 |
| Geisler, CH | 2 |
| Ghia, P | 1 |
| Hillmen, P | 2 |
| Moreno, C | 1 |
| Stilgenbauer, S | 1 |
| Barrientos, JC | 1 |
| Byrd, JC | 2 |
| Zhou, C | 1 |
| Ninomoto, J | 1 |
| James, DF | 2 |
| Kipps, TJ | 2 |
| Bond, DA | 1 |
| Alinari, L | 1 |
| Maddocks, K | 2 |
| Woyach, JA | 1 |
| Smucker, K | 1 |
| Smith, LL | 1 |
| Lozanski, A | 1 |
| Zhong, Y | 1 |
| Ruppert, AS | 1 |
| Lucas, D | 1 |
| Williams, K | 1 |
| Zhao, W | 1 |
| Rassenti, L | 1 |
| Ghia, E | 1 |
| Mantel, R | 1 |
| Jones, J | 3 |
| Flynn, J | 1 |
| O'Brien, S | 3 |
| Furman, RR | 1 |
| Clow, F | 1 |
| Lozanski, G | 1 |
| Johnson, AJ | 1 |
| Rossi, D | 1 |
| Gaidano, G | 1 |
| Herman, SE | 2 |
| Niemann, CU | 1 |
| Farooqui, M | 2 |
| Mustafa, RZ | 2 |
| Lipsky, A | 1 |
| Saba, N | 1 |
| Martyr, S | 1 |
| Soto, S | 1 |
| Valdez, J | 1 |
| Gyamfi, JA | 1 |
| Maric, I | 1 |
| Calvo, KR | 1 |
| Pedersen, LB | 1 |
| Liu, D | 1 |
| Marti, GE | 1 |
| Aue, G | 1 |
| Thompson, PA | 1 |
| Wierda, WG | 1 |
| Keating, MJ | 1 |
| Furtado, M | 1 |
| Wang, ML | 1 |
| Munneke, B | 1 |
| McGreivy, J | 1 |
| Beaupre, DM | 1 |
| Rule, S | 1 |
| Wong, DH | 1 |
| Jeyakumar, D | 1 |
| Quintela, A | 1 |
| Sujobert, P | 1 |
| Callet-Bauchu, E | 1 |
| Salles, G | 1 |
| Baseggio, L | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase Ib Dose Finding Study of Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765) Plus Lenalidomide / Rituximab in Relapsed or Refractory Mantle Cell Lymphoma (MCL)[NCT02446236] | Phase 1 | 27 participants (Actual) | Interventional | 2015-06-18 | Active, not recruiting | ||
| A Phase II Study of PCI-32765 for Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Who Need Therapy and Are Older Than 65 or Have a 17p Deletion[NCT01500733] | Phase 2 | 86 participants (Actual) | Interventional | 2012-01-05 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"The primary endpoint was response after 6 cycles of therapy. Overall response rate was calculated as complete response plus partial response, based on the International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2008 criteria.as follows:~Complete response (CR): all group A and group B criteria are met~Group A criteria: resolution of enlarged lymph nodes, normal size spleen and liver, absolute lymphocyte count < 4,000/uL, normocellular bone marrow with < 30% lymphocytes without nodules~Group B criteria: improved blood count (platelet count > 100,000/uL, hemoglobin > 11.0 g/dL, neutrophils > 1,500/uL)~Partial response (PR): at least 2 of the group A criteria plus one of the group B criteria are met~Group A criteria: >=50% decrease in target lymph nodes, >=50% decrease in spleen size, >=50% decrease in liver size, 50% reduction in marrow infiltrates~Group B criteria: platelet count > 100,000/uL, hemoglobin > 11.0 g/dL, neutrophils > 1,500/uL" (NCT01500733)
Timeframe: 6 months
| Intervention | percentage of participants (Number) |
|---|---|
| Elderly Cohort | 93.9 |
| TP53 Cohort | 95.8 |
4 reviews available for adenine and Lymphocytosis
| Article | Year |
|---|---|
An oral drug for chronic lymphocytic leukemia.
Topics: Adenine; Administration, Oral; Antineoplastic Agents; Atrial Fibrillation; Hemorrhage; Humans; Hyper | 2020 |
Optimising outcomes for patients with chronic lymphocytic leukaemia on ibrutinib therapy: European recommendations for clinical practice.
Topics: Adenine; Anticoagulants; Antineoplastic Agents; Arthralgia; Atrial Fibrillation; Diabetes Mellitus, | 2018 |
Bruton tyrosine kinase inhibitors for the treatment of mantle cell lymphoma: review of current evidence and future directions.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antigens, CD20; Antineoplastic Agents; Antineoplastic | 2019 |
B cell receptor inhibition as a target for CLL therapy.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Age Factors; Atrial Fibrillation; Diarrhea; Hemorrhage | 2016 |
2 trials available for adenine and Lymphocytosis
| Article | Year |
|---|---|
Characterizing the kinetics of lymphocytosis in patients with chronic lymphocytic leukemia treated with single-agent ibrutinib.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Biomarkers; Follow-Up Studies; Humans; Leukemia, Lymph | 2019 |
Ibrutinib-induced lymphocytosis in patients with chronic lymphocytic leukemia: correlative analyses from a phase II study.
Topics: Adenine; Aged; Blood Viscosity; Female; Hemoglobins; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; | 2014 |
10 other studies available for adenine and Lymphocytosis
| Article | Year |
|---|---|
Population PK-PD Modeling of Circulating Lymphocyte Dynamics in Chronic Lymphocytic Leukemia Patients Under Ibrutinib Treatment.
Topics: Adenine; Adult; Aged; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocyte Count; Lymp | 2021 |
Severe Lymphocytosis in a Case of Diffuse Large B-Cell Lymphoma Treated by Ibrutinib
Topics: Adenine; Humans; Lymphocytosis; Lymphoma, Large B-Cell, Diffuse; Patient Acuity; Piperidines | 2021 |
Analysis of Efficacy and Tolerability of Bruton Tyrosine Kinase Inhibitor Ibrutinib in Various B-cell Malignancies in the General Community: A Single-center Experience.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Atrial Fibrillation; B-Lympho | 2017 |
Functional and clinical relevance of VLA-4 (CD49d/CD29) in ibrutinib-treated chronic lymphocytic leukemia.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Cell Adhesion; Humans; Immunoglobulin M; Integrin alph | 2018 |
Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; CD40 Ligand; Disease-F | 2014 |
Lymphocytosis and ibrutinib treatment of CLL.
Topics: Adenine; Female; Humans; Lymphocytosis; Male; Piperidines; Pyrazoles; Pyrimidines | 2014 |
Trisomy 12 is associated with an abbreviated redistribution lymphocytosis during treatment with the BTK inhibitor ibrutinib in patients with chronic lymphocytic leukaemia.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Chromosomes, Human, Pair 12; Female; Humans; Leukemia, Lymp | 2015 |
Ibrutinib-associated lymphocytosis corresponds to bone marrow involvement in mantle cell lymphoma.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Bone Marrow; Humans; Lymphocytosis; Lymphoma, Mantle-C | 2015 |
Treatment with Ibrutinib Inhibits BTK- and VLA-4-Dependent Adhesion of Chronic Lymphocytic Leukemia Cells In Vivo.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Cell Adhesion; Female; Fibronectins; Humans; Int | 2015 |
Ibrutinib-Induced Lymphocytosis: Cytological Features.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antineoplastic Agents; Chromo | 2017 |